Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University
Conclusion: We confirm that low dose of vemurafenib is effective and safe in the vast majority of patients with HCL. This small-molecule oral treatment allows to gain valuable time-months or even years-before further, usually parenteral treatment options have to be given or before previous treatment has to be repeated. There are also promising data supporting the combination of vemurafenib with other drugs for the treatment of HCL patients which could provide even further possibility to bridge treatment.PMID:38025907 | PMC:PMC10663343 | DOI:10.3389/pore.2023.1611378
Source: Pathology Oncology Research - Category: Pathology Authors: Kata Ferenczi Zs ófia Flóra Nagy Ildik ó Istenes Hanna Eid Csaba B ödör Botond Tim ár Judit Demeter Source Type: research
More News: Cancer & Oncology | Hairy Cell Leukemia | Internal Medicine | Leukemia | Pathology | Study